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ABSTRACT
The in-vitro activity of telithromycin and compa-
rator antibacterial agents was determined against
clinical isolates of Legionella pneumophila collected
in the PROTEKT surveillance study. In total, 133
isolateswere collected between 1999 and 2004 from
13 countries (Australia, Belgium, Czech Republic,
France, Germany, Hungary, Ireland, Italy, Japan,
Portugal, Spain, Sweden and the USA). MICs
were determined by broth microdilution.
Telithromycin maintained activity between Year 1
(MIC90 0.015 mg ⁄L) andYear 5 (MIC90 0.03 mg ⁄L),
as did the comparator antibacterial agents. Telith-
romycin appears to be a candidate for coverage of
legionellosis in the empirical treatment of commu-
nity-acquired respiratory tract infection.
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Legionella pneumophila, a Gram-negative intracel-
lular bacterium, is an important atypical pathogen
of the lower respiratory tract that can cause
community-acquired pneumonia (CAP) [1].
Legionella spp. are thought to be implicated in
0.5–6.0% of cases of CAP among patients admit-
ted to hospital [2]. More than 10 000 cases of
Legionella infection were reported throughout
Europe between 2000 and 2002. Country-speciﬁc
incidences ranged from 0 to 34 cases ⁄million
individuals [3]. Despite improved diagnostic tests
[3], estimates suggest that only 2–10% cases of
legionellosis are reported [1]. Risk-factors for
Legionella infection include smoking, advanced
age and immunosuppression [1], but a substantial
proportion of cases occur in non-smokers and
patients aged <55 years [4]. L. pneumophila is esti-
mated to cause >90% of all Legionella infections [5].
The Infectious Diseases Society of America
recommends that empirical antibacterial therapy
for outpatients with CAP should cover atyp-
ical ⁄ intracellular organisms [2]. CAP suspected to
be caused by L. pneumophila should be treated
with azithromycin or a respiratory ﬂuoroquino-
lone if the patient requires hospitalisation, or with
any macrolide, doxycycline or a ﬂuoroquinolone
if the patient is treated as an outpatient [2]. Delay
in commencing antimicrobial treatment is associ-
ated with increased mortality [6].
Telithromycin is active in vitro against typical
community-acquired respiratory tract infection
pathogens, including penicillin- and macrolide-
resistant strains of Streptococcus pneumoniae [7].
Telithromycin is concentrated within polymor-
phonuclear neutrophils [8] and shows high-level
activity against atypical intracellular pathogens,
including L. pneumophila [9].
PROTEKT (Prospective Resistant Organism
Tracking and Epidemiology for the Ketolide
Telithromycin) is a longitudinal, global, multicen-
tre surveillance study that includes centres
throughout Europe, the Middle East and Far East,
the USA, Canada, Australia and South Africa [10].
Between Year 1 (1999–2000) and Year 5 (2003–
2004), 26 centres in 13 countries (Australia,
Belgium, the Czech Republic, France, Germany,
Hungary, Ireland, Italy, Japan, Portugal, Spain,
Sweden and the USA) provided 133 clinical
isolates of L. pneumophila from patients with
community-acquired respiratory tract infection.
Identiﬁcation and testing of isolates was per-
formed at a central laboratory (G. R. Micro Ltd,
London, UK). Most patients from whom cultures
were obtained were male (75.7%; 81 ⁄ 107), and all
were aged ‡15 years, with 71.7% (76 ⁄ 106) being
aged 15–64 years, and 28.3% (30 ⁄ 106) being aged
>65 years. An associated clinical diagnosis was
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available for 98 of the patients: 96.9% (95 ⁄ 98) of
isolates were from patients diagnosed with CAP,
and three isolates were from patients with chronic
obstructive airway disease. The source of the
sample was speciﬁed for 107 (80.5%) isolates. The
majority of isolates were cultured from sputum
(55.1%; 59 ⁄ 107) or bronchoalveolar lavage ﬂuid
(41.1%; 44 ⁄ 107). The remainder were from naso-
pharyngeal swabs (1.9%; 2 ⁄ 107), middle ear ﬂuid
(0.9%; 1 ⁄ 107) or throat swabs (0.9%; 1 ⁄ 107).
MICs were determined at the central laboratory
using Sensititre microtitre plates containing
freeze-dried antimicrobial agents (Trek Diagnostic
Systems, East Grinstead, UK). The inoculating
medium was made by adding 10.5 g of Mueller–
Hinton broth powder and 5 g of yeast extract to
400 mL of distilled water, sterilising, and then
adding 50 mL of whole lysed horse blood and
50 mL of Legionella BCYE growth supplement
(Oxoid, Basingstoke, UK) after cooling. A
0.5 · MacFarland suspension of each isolate was
suspended in 5 mL of cation-adjusted Mueller–
Hinton broth, and 50 lL of this was added to an
11-mL aliquot of inoculating medium. The pre-
pared inoculum (100 lL) was then added to each
well of a microtitre plate and incubated at 35C for
24–72 h in air (the incubation period for individ-
ual isolates was dependent on the growth rate).
Telithromycin and levoﬂoxacin were the most
active agents tested, while the macrolides were
somewhat less active. Telithromycin MIC50 and
MIC90 values for L. pneumophila were 0.015 mg ⁄L
and 0.03 mg ⁄L, respectively (range 0.004–
0.06 mg ⁄L). The telithromycin MIC distribution
did not vary greatly among the years of the study,
and there was no signiﬁcant change in telithro-
mycin MIC90 values (Table 1). Despite minor
variations in the respective MIC50 and MIC90
values, the MIC ranges for all antibacterial agents
tested remained stable over the 5-year study
period (Table 1).
Longitudinal surveillance data are essential for
monitoring changes in bacterial susceptibility to
antibacterial agents over time. The present data
show that telithromycin sustained high-level
in-vitro activity against clinical isolates of L. pneu-
mophila throughout the ﬁrst 5 years of the PRO-
TEKT study, despite use of this drug in many
European countries, with 22 million patient pre-
scriptions worldwide (Sanoﬁ-Aventis, data on
ﬁle). This international collection of isolates,
obtained almost entirely from patients with
CAP, should allow a robust evaluation of the
activity of the antibacterial agents tested.
A previous study of clinical isolates and labor-
atory strains of L. pneumophila broadly ranked the
MIC50 values obtained using broth dilution meth-
odology for the antimicrobial agents tested in the
following order: ﬂuoroquinolones < ketolides <
macrolides [11]. The rank order of antimicrobial
class activity (MIC50) against Legionella spp.
observed in the present analysis was in general
agreement with this previous observation. Levo-
ﬂoxacin showed in-vitro activity similar to telith-
romycin (one dilution less), while azithromycin,
clarithromycin and erythromycin were less active.
As Legionella spp. multiply inside alveolar macr-
ophages and monocytes, models of the intracellu-
lar activity of antibacterial agents are essential in
order to predict clinical efﬁcacy. These models
support the same relative order of activity for
ﬂuoroquinolones, ketolides and macrolides.
Telithromycin showed concentration-dependent
bactericidal activity against L. pneumophila within
Table 1. MICs of telithromycin and comparator antimicrobial agents for clinical isolates of Legionella pneumophila
Agent
MIC (mg ⁄L)
Year 1 (n = 26) Year 2 (n = 31) Year 3 (n = 19) Year 4 (n = 24) Year 5 (n = 33) Total (n = 133)a
MIC50 MIC90 Range MIC50 MIC90 Range MIC50 MIC90 Range MIC50 MIC90 Range MIC50 MIC90 Range MIC50 MIC90 Range
Azithromycin £0.06 £0.06 £0.06–
)0.12
0.12 0.25 £0.06–
)0.5
0.12 0.5 £0.06–
0.5
£0.06 £0.06 £0.06–
0.25
£0.06 0.25 £0.06–
0.5
£0.06 0.25 £0.06–
0.5
Clarithromycin £0.25 £0.25 £0.25–
£0.25
£0.25 £0.25 £0.25––
0.5
£0.25 £0.25 £0.25–
£0.25
£0.25 £0.25 £0.25–
£0.25
£0.25– £0.25 £0.25–
£0.25
£0.25 £0.25– £0.25–
0.5
Erythromycin £0.25 £0.25 £0.25–
0.5
£0.25 0.5 £0.25–
0.5
£0.25 0.5 £0.25–
0.5
£0.25 £0.25 £0.25–
0.5
ND ND ND £0.25 0.5 £0.25–
0.5
Levoﬂoxacin £0.008 0.015 £0.008–
0.015
0.015 0.015 £0.008–
0.03
£0.008 0.015 £0.008–
0.015
£0.008 £0.008 £0.008–
£0.008
£0.008 0.015 £0.008–
0.015
£0.008 0.015 £0.008
0.03
Telithromycin 0.008 0.015 0.004–
0.015
0.015 0.03 0.008–
0.06
0.015 0.03 0.008–
0.03
0.008 0.03 0.004–
0.03
0.015 0.03 0.004–
0.06
0.015 0.03 0.004–
0.06
aFor erythromycin, total number of isolates = 100.
ND, not determined.
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human monocytes at concentrations as low as
0.25 mg ⁄L [12]. The growth of L. pneumophila was
also suppressed for 2–4 days after telithromycin
was removed from the medium, while regrowth
occurred after levoﬂoxacin ‘wash-out’ [12]. This
rapid ‘wash-out’ effect from human monocytes
was also observed with gemiﬂoxacin [13]. How-
ever, retention of both gemiﬂoxacin [14] and
trovoﬂoxacin [15]within guinea-pig alveolarmacr-
ophages has been observed, suggesting that retent-
ion of ﬂuoroquinolones might be both drug- and
cell-type-speciﬁc. The prolonged post-antibiotic
effect of telithromycin might be explained by the
retention of ketolides within human cells. Telith-
romycin is signiﬁcantly more effective at reducing
the viable intracellular count ofL. pneumophila than
is erythromycin in an HL-60 human macrophage-
like cell line [11]. The same model ranked the
bactericidal activity of telithromycin between the
macrolides and the ﬂuoroquinolones [11].
The macrolides and the ﬂuoroquinolones are
currently recommended options for the treatment
of legionellosis, depending on the severity of the
infection [2]. Prospective observational studies
among patients hospitalised with a Legionella
infection that had been diagnosed using the
urinary antigen test have shown no difference
between macrolides (i.e., erythromycin or clarith-
romycin) and ﬂuoroquinolones in terms of com-
plication or mortality rates [16,17]. However,
compared with macrolides, ﬂuoroquinolones
were associated with shorter times to deferves-
cence and clinical stability, and a shorter duration
of hospitalisation, suggesting that the use of more
active agents may reduce the direct costs associ-
ated with hospitalisation. Telithromycin has also
been recommended for use in treating Legionella
CAP in outpatients [18], although few clinical data
are available. Pooled data from eight international
studies of telithromycin (800 mg once-daily for 5–
10 days) in the treatment of mild-to-moderate
CAP showed that telithromycin clinically cured
13 ⁄ 13 patients infected by L. pneumophila [19].
Thus, it seems that telithromycin has potential as
a useful alternative therapy for coverage against
legionellosis in the empirical treatment of com-
munity-acquired respiratory tract infections.
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